Jason Hsu, MD
Ophthalmology · Plymouth Meeting, PANPI 1548218787
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Chugai Pharmaceutical Co., Ltd. accounts for 72.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $15,357, more than ten times the $29 reported in 2022. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $1498.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chugai Pharmaceutical Co., Ltd.$13K
- Astellas Pharma US Inc$3K
- Neurotech Pharmaceuticals, Inc.$2K
- Biosense Webster, Inc.$133
- Genentech USA, Inc.$96
- Regeneron$29
Across 88 payments — averaging $11,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$544K
- Jazz Pharmaceuticals Inc.$258K
- Boehringer Ingelheim$86K
- Astellas Pharma Global Development$81K
- Regeneron$13K
- Boehringer Ingelheim International GmbH$6K
- plus $4K from 1 others
What the payments were for
- Consulting fees$8,56648%
- Travel & lodging$9,08150%
- Food & beverage$3352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 4 | $13,086 |
| Astellas Pharma US Inc | 1 | $2,500 |
| Neurotech Pharmaceuticals, Inc. | 2 | $2,138 |
| Biosense Webster, Inc. | 1 | $133 |
| Genentech USA, Inc. | 3 | $96 |
| Regeneron | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$2,500
- QDOT MICRO$133
How this compares
$17,983 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 168 | $7,959 |
| Ketorolac Tromethamine | 69 | $1,386 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 67 | $965 |
| Ofloxacin | 58 | $759 |
| Dorzolamide Hcl | 18 | $242 |
| Brimonidine Tartrate | 20 | $214 |
| ErythromycinErythromycin Base | 13 | $198 |
| Diclofenac Sodium | 13 | $134 |
| Timolol Maleate | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.